A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Trial Profile

A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Feb 2017 Status changed from recruiting to completed.
    • 08 Dec 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top